Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Instil Bio is a clinical-stage biotechnology company developing tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors, with lead programs targeting melanoma, non-small cell lung cancer, and head/neck cancers. The company is pre-revenue with a $100M market cap, burning approximately $100M annually in operating cash, and faces critical clinical trial readouts that will determine survival. With a 34.45x current ratio and minimal debt, the company has runway but requires successful trial outcomes or capital raises to continue operations beyond 2026-2027.
Instil Bio is developing autologous TIL therapies where patient tumors are biopsied, T-cells are extracted and expanded ex vivo over 2-3 weeks, then reinfused to attack cancer cells. The company's differentiation centers on manufacturing process improvements (Gen2/Gen3 platforms) aimed at reducing production time from 22 days to potentially 8-10 days and improving cell potency. Revenue generation depends entirely on FDA approval, requiring successful Phase 2/3 trial data demonstrating superior efficacy versus standard-of-care in specific tumor types. Pricing power would derive from limited competition in TIL space (Iovance is primary competitor) and high unmet need in refractory solid tumors, but faces reimbursement pressure given CAR-T therapy cost scrutiny. The business model requires significant upfront manufacturing infrastructure investment ($50M+ for commercial-scale facilities) before generating revenue.
Clinical trial data readouts - particularly overall response rates (ORR), duration of response (DOR), and progression-free survival (PFS) in lead melanoma and NSCLC programs versus historical benchmarks
FDA regulatory interactions - IND clearances for new indications, Fast Track/Breakthrough Therapy designations, or clinical hold notifications
Manufacturing platform milestones - Gen2/Gen3 process validation data showing reduced production timelines or improved cell characteristics
Capital raises and cash runway updates - equity offerings, debt financing, or partnership deals that extend operational runway beyond 12-18 months
Competitive developments from Iovance Biotherapeutics (primary TIL competitor) including their commercial launch progress and market penetration data
Binary clinical trial risk - single failed Phase 2/3 readout could render company's platform value near-zero given limited cash to pivot to alternative programs
Manufacturing complexity and scalability - autologous TIL therapy requires patient-specific production with 2-3 week turnaround, creating operational bottlenecks and quality control challenges that have plagued other cell therapy companies
Reimbursement uncertainty - payers increasingly scrutinizing $400K+ oncology treatments, and CMS may impose restrictive coverage policies or outcomes-based contracts that limit commercial potential
Competitive obsolescence risk - CAR-T therapies, bispecific antibodies, and other immunotherapies advancing rapidly could make TIL approach non-competitive before Instil reaches market
Iovance Biotherapeutics has 2-3 year head start with FDA-approved TIL therapy (Amtagvi for melanoma, approved February 2024), establishing reimbursement pathways and treatment center networks before Instil can launch
Large pharma CAR-T franchises (Bristol Myers Squibb, Gilead/Kite, Novartis) expanding into solid tumors with off-the-shelf allogeneic approaches that avoid patient-specific manufacturing delays
Liquidity crisis risk - with $100M annual burn and approximately $100M-$150M estimated cash (based on 34.45 current ratio), company likely needs financing within 12-18 months, potentially at distressed valuations given 69% six-month stock decline
Dilution risk - equity raises at current $100M market cap would be highly dilutive to existing shareholders, potentially requiring 50%+ dilution to raise sufficient capital for pivotal trial completion
Going concern risk - auditors may include going concern language in future filings if cash runway drops below 12 months without clear financing path
low - Clinical trial timelines and FDA approval processes are largely insulated from GDP fluctuations. However, severe recessions could impact ability to raise capital at favorable terms and delay hospital/payer adoption post-approval due to budget constraints. Biotech sector funding availability is more sensitive to risk appetite than economic cycles.
High sensitivity through valuation multiple compression. As pre-revenue biotech, Instil's valuation is based on discounted future cash flows 5-10 years out, making it highly sensitive to discount rate changes. Rising rates from current levels compress NPV of potential future revenues and make speculative biotech less attractive versus fixed income. Additionally, higher rates increase cost of debt financing if company pursues non-dilutive capital. The stock has declined 65% over past year partly reflecting 2024-2025 rate environment.
Minimal direct credit exposure given pre-revenue status and limited debt (0.71 D/E ratio). However, tightening credit conditions reduce availability of venture debt or structured financing options that could extend runway without equity dilution. Broader biotech sector funding environment (VC/IPO markets) is credit-sensitive, affecting ability to raise follow-on capital.
High-risk growth/speculation - attracts biotech-specialized hedge funds, venture investors, and retail speculators willing to accept binary clinical trial outcomes for potential 5-10x returns if trials succeed. Not suitable for value or income investors given pre-revenue status and negative cash flow. Current 65% one-year decline has attracted some distressed/special situations investors betting on oversold bounce or takeout potential.
high - Clinical-stage biotech with $100M market cap exhibits extreme volatility around data catalysts (30-50% single-day moves common on trial readouts). Beta likely exceeds 2.0x relative to broader market. Stock down 69% over six months reflects both sector-wide biotech weakness and company-specific clinical/financing concerns. Daily trading volume thin, creating liquidity risk and wide bid-ask spreads.